Cargando…

The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population

The prognostic heterogeneity of multiple myeloma (MM) is largely due to different genetic abnormalities. Cytogenetic analysis has revealed that most of MM harbor chromosome aberrations. Amplification of 1q21 is one of the most common chromosomal aberrations. Interphase fluorescence in situ hybridiza...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Wenjun, Guo, Rui, Qu, Xiaoyan, Qiu, Hairong, Li, Jianyong, Zhang, Run, Chen, Lijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716762/
https://www.ncbi.nlm.nih.gov/pubmed/26834489
http://dx.doi.org/10.2147/OTT.S95381
_version_ 1782410584149458944
author Yu, Wenjun
Guo, Rui
Qu, Xiaoyan
Qiu, Hairong
Li, Jianyong
Zhang, Run
Chen, Lijuan
author_facet Yu, Wenjun
Guo, Rui
Qu, Xiaoyan
Qiu, Hairong
Li, Jianyong
Zhang, Run
Chen, Lijuan
author_sort Yu, Wenjun
collection PubMed
description The prognostic heterogeneity of multiple myeloma (MM) is largely due to different genetic abnormalities. Cytogenetic analysis has revealed that most of MM harbor chromosome aberrations. Amplification of 1q21 is one of the most common chromosomal aberrations. Interphase fluorescence in situ hybridization was applied to detect the 1q21 amplification in 86 Chinese patients with newly diagnosed MM. Amp(1q21) was found in totally 40 of 86 (46.5%) cases, among which 29 with three copies of 1q21 and eleven with at least four copies of 1q21. Further analysis revealed a significant difference of overall survival and progression-free survival among the three arms (P<0.05). Bortezomib could not significantly improve the overall survival for patients with 1q21 amplification (P>0.05). These findings suggest that 1q21 amplification with four copies or more is prognostic factor for adverse outcomes of MM patients. Furthermore, chromosome 1q21 gains predicted a poor overall survival even in those receiving bortezomib-based regimens.
format Online
Article
Text
id pubmed-4716762
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-47167622016-02-01 The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population Yu, Wenjun Guo, Rui Qu, Xiaoyan Qiu, Hairong Li, Jianyong Zhang, Run Chen, Lijuan Onco Targets Ther Original Research The prognostic heterogeneity of multiple myeloma (MM) is largely due to different genetic abnormalities. Cytogenetic analysis has revealed that most of MM harbor chromosome aberrations. Amplification of 1q21 is one of the most common chromosomal aberrations. Interphase fluorescence in situ hybridization was applied to detect the 1q21 amplification in 86 Chinese patients with newly diagnosed MM. Amp(1q21) was found in totally 40 of 86 (46.5%) cases, among which 29 with three copies of 1q21 and eleven with at least four copies of 1q21. Further analysis revealed a significant difference of overall survival and progression-free survival among the three arms (P<0.05). Bortezomib could not significantly improve the overall survival for patients with 1q21 amplification (P>0.05). These findings suggest that 1q21 amplification with four copies or more is prognostic factor for adverse outcomes of MM patients. Furthermore, chromosome 1q21 gains predicted a poor overall survival even in those receiving bortezomib-based regimens. Dove Medical Press 2016-01-12 /pmc/articles/PMC4716762/ /pubmed/26834489 http://dx.doi.org/10.2147/OTT.S95381 Text en © 2016 Yu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Yu, Wenjun
Guo, Rui
Qu, Xiaoyan
Qiu, Hairong
Li, Jianyong
Zhang, Run
Chen, Lijuan
The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population
title The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population
title_full The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population
title_fullStr The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population
title_full_unstemmed The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population
title_short The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population
title_sort amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a chinese population
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716762/
https://www.ncbi.nlm.nih.gov/pubmed/26834489
http://dx.doi.org/10.2147/OTT.S95381
work_keys_str_mv AT yuwenjun theamplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation
AT guorui theamplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation
AT quxiaoyan theamplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation
AT qiuhairong theamplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation
AT lijianyong theamplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation
AT zhangrun theamplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation
AT chenlijuan theamplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation
AT yuwenjun amplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation
AT guorui amplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation
AT quxiaoyan amplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation
AT qiuhairong amplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation
AT lijianyong amplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation
AT zhangrun amplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation
AT chenlijuan amplificationof1q21isanadverseprognosticfactorinpatientswithmultiplemyelomainachinesepopulation